Lexington, KYNCT06789159Now EnrollingIRB Ready

Diffuse Large B Cell Lymphoma Refractory Clinical Trial in Lexington, KY

Access cutting-edge diffuse large b cell lymphoma refractory treatment through this clinical trial at a research site in Lexington. Study-provided care at no cost to qualified participants.

Sponsored by Pierluigi Porcu

Quick Self-Assessment

See if you qualify for this Lexington location

Preparing your pre-screening questions…

Expert Care in Lexington

Access diffuse large b cell lymphoma refractory specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related diffuse large b cell lymphoma refractory treatment provided free

Apply for This Lexington Location

Check if you qualify for this diffuse large b cell lymphoma refractory clinical trial in Lexington, KY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lexington

    Convenient for KY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lexington site if eligible
  4. 4Begin participation

About This Diffuse Large B Cell Lymphoma Refractory Study in Lexington

This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.

Sponsor: Pierluigi Porcu

Who Can Participate

Inclusion Criteria

Informed consent obtained prior to any protocol mandated assessment.
Age ≥ 18 years.
Patient must have relapsed or refractory EBV-positive DLBCL after a minimum of 2 prior regimens of systemic therapy.
Patient must have exhausted all available standard of care treatment options that could potentially provide clinical benefit.
Toxicities related to prior therapy must have returned to Grade 1 or less, or if chronic must be stable. Peripheral neuropathy must be Grade 2 or less
Prior anti-cancer treatment must have been completed greater than 2 weeks prior to study day 1.
Patients must have measurable disease, as defined by IWG 2007 criteria.
ECOG performance status score of ≤2
Adequate organ function as defined by the following criteria:
Absolute neutrophil count \> 1,500/microl (stable off any growth factor within 1 week of study drug administration)
Hemoglobin \> 9 g/dL (transfusion to achieve this level is permitted)
Platelet count \> 75,000/microl (transfusion to achieve this level is NOT permitted)
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN);
Total serum bilirubin ≤ 1.5 x ULN;
Creatinine clearance≥ 60 ml/min as calculated per Cockcroft and Gault equation.
Urinary protein \< 2+ by dipstick. If dipstick ≥ 2+, then a 24-hour urine collection can be done, and the patient may enter only if urinary protein is \< 1 g/24 hour;
Sexually active patients will agree to utilize birth control method during the study and for 18 weeks after the study is concluded, using effective birth control methods as defined in https://www.cdc.gov/reproductivehealth/unintendedpregnancy/pdf/contraceptive\_methods\_508.pdf. See Protocol Appendix C.
Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures. 4.2

Exclusion Criteria

Patients with severe or active symptomatic cardiopulmonary diseases (unstable angina and/or congestive heart failure or peripheral vascular disease within the last 12 months; chronic obstructive pulmonary disease exacerbation other respiratory illness requiring hospitalization) or clinically significant psychiatric disorders; patents with effectively treated conditions (e.g. stenting for CAD) are eligible.
Patients with metastatic disease with active central nervous system (CNS) involvement, defined as parenchymal brain or leptomeningeal involvement.
Concurrent administration of herbal preparations.
A serious uncontrolled medical disorder or active infection which would impair the ability of the subject to receive protocol therapy or whose control may be jeopardized by the complications of this therapy.
Patients currently taking drugs that inhibit or induce OATP1B1 or OATP1B3 within 5 half- lives of that agent. Examples are included in Appendix B.
Patients currently taking drugs that are proton pump inhibitors (PPIs) within 5 half- lives of that agent. Examples are included in Appendix B.
Patients who have received a prior organ allograft or allogeneic bone marrow transplant are eligible but must have no evidence of active GVHD and be off immunosuppressive drugs.
Current non-prescription drug or alcohol dependence;
For all female patients, pregnancy or breastfeeding.
All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.
Patients with corrected QT by Fridericia's formula (QTcF) of \>470 ms are excluded.
Patients with Post-Transplant Lymphoproliferative Disease (PTLD) are excluded.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lexington?

Yes, this clinical trial (NCT06789159) has an active research site in Lexington, KY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diffuse Large B Cell Lymphoma Refractory Treatment Options in Lexington, KY

If you're searching for diffuse large b cell lymphoma refractory treatment options in Lexington, KY, this clinical trial (NCT06789159) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lexington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced diffuse large b cell lymphoma refractory specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diffuse large b cell lymphoma refractory clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Lexington, KY

See all lymphoma clinical trials recruiting in Lexington — not just this study.

Browse Lymphoma Trials in Lexington →

Browse More Trials by Condition

Lymphoma TrialsDiffuse Large B-Cell Lymphoma TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Lexington?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lexington, KY